NCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
42 trialsNCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT05816642 2023-04-18
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
RenJi Hospital
Phase NA Unknown
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT01743482 2021-05-14
Pazotest-01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT02555748 2021-01-12
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT04462445 2020-07-10
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01221506 2020-03-26
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT03379012 2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03519542 2019-09-18
SOGANG
Spanish Oncology Genito-Urinary Group
Completed
NCT02729194 2019-06-10
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT01832259 2018-12-12
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01158521 2018-09-12
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01385228 2018-06-06
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Phase 1 Completed
NCT02282579 2018-04-26
SPAZO
Spanish Oncology Genito-Urinary Group
Completed
NCT01361113 2018-04-25
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02089802 2017-08-18
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Phase 2 Terminated
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01599832 2017-06-08
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
University of Chicago
Phase NA Terminated
NCT02307474 2016-03-03
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT00731211 2015-05-20
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02324803 2014-12-24
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
Southern China Urology Cancer Consortium
Phase 2 Unknown
NCT02208128 2014-08-04
MORE
Heidelberg University
Phase NA Unknown
NCT01408004 2014-07-16
ROPETAR
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Completed
NCT01577784 2014-03-12
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00945477 2013-11-18
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT01265940 2012-10-10
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Lukas-Krankenhaus GmbH
Phase 1/2 Completed